Bisimidazolium Salt Glycosyltransferase Inhibitors Suppress Hepatocellular Carcinoma Progression In Vitro and In Vivo

Bisimidazolium Salt Glycosyltransferase Inhibitors Suppress Hepatocellular Carcinoma Progression In Vitro and In Vivo

Hepatocellular carcinoma is a leading cause of cancer death, and the disease progression has been related to glycophenotype modifications. Previously synthesized bisimidazolium salts (C20 and C22) have been shown to selectively inhibit the activity of glycosyltransferases in cultured cancer cell hom...

Full description

Bibliographic Details
Main Authors: Xue Luan, Ming Sun, Xue Zhao, Jingyi Wang, Ye Han, Yin Gao
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Pharmaceuticals
Subjects:
glycosyltransferase inhibitor
anticancer agents
cytotoxicity
ER stress
cell-cycle and apoptosis
Online Access:https://www.mdpi.com/1424-8247/15/6/716

Internet

https://www.mdpi.com/1424-8247/15/6/716

Similar Items